Sanofi makes changes to Executive Committee

Supporting the French pharmaceutical firm's 2020 Strategic Roadmap

Sanofi's Chief Executive Olivier Brandicourt has announced a number of changes to the company's Executive Committee, supporting the French drugmaker's 2020 Strategic Roadmap.

As of 1 June, the Executive Committee, chaired by Olivier Brandicourt, will comprise the following members:

  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines and Emerging Markets
  • Jérôme Contamine, Executive Vice President, Finance
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular
  • Carsten Hellmann, Executive Vice President and General Manager of Merial. (Hellmann has accepted a position as President and CEO of ALK but will stay with Sanofi until the end of the year to support the strategic business swap project with Boehringer Ingelheim)
  • Karen Linehan, Executive Vice President, Legal Affairs and General Counsel
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs
  • Muzammil Mansuri, Executive Vice President, Strategy & Business Development
  • David Meeker, Executive Vice President and General Manager of Sanofi Genzyme
  • Ameet Nathwani, Executive Vice President, Medical Affairs
  • Roberto Pucci, Executive Vice President, Human Resources
  • Elias Zerhouni, President, Global Research & Development

The company has also announced that Pascale Witz, Executive Vice President, Diabetes & Cardiovascular, will leave the company on 1 June. Since joining Sanofi in July 2013, Witz has been a champion for driving a patient-focused, integrated-care approach to how Sanofi operates. She was instrumental in signing collaborations with Verily Life Sciences (a subsidiary of Google) and Hanmi Pharmaceuticals.

In addition, Sanofi plans to name at a later date an Executive Vice President, Consumer Healthcare (CHC) who will be a member of the Executive Committee. This person will lead a newly created CHC global business unit, which will be formed following the anticipated completion of the business swap announced in December 2015 that consists of Sanofi's animal health business Merial and Boehringer Ingelheim's consumer healthcare (CHC) business. The transaction would allow Sanofi to become a global leader in CHC.

Finally, Suresh Kumar, Executive Vice President, External Affairs, has decided to return to the US for personal reasons. Given the challenging US operating environment and impending change in government leadership, Suresh has agreed to continue to represent Sanofi's interest in the US until the end of this year. Olivier Brandicourt will serve as acting head of External Affairs until a replacement is found to succeed Suresh.